Literature DB >> 17420962

Differential expressions of cyclin D1 associated with better prognosis of cancers of ampulla of Vater.

Ming-Chug Chang1, Yu-Ting Chang, Chia-Tung Sun, Yen-Feng Chiu, Jaw-Town Lin, Yu-Wen Tien.   

Abstract

BACKGROUND: Periampullary cancers, the incidence of which increases gradually with industrialization, still pose a significant challenge to clinicians and researchers. Specifically, the role of cell-cycle proteins and tumor suppressor genes in these cancers is not yet clear. Recent studies have revealed that genes and proteins related to cell cycle and apoptosis regulation may be involved in pancreatic carcinogenesis.
METHODS: Tissue samples were obtained from patients with periampullary cancers who underwent surgery at the National Taiwan University Hospital without receiving previous chemotherapy or radiation therapy. All periampullary cancer tissue samples were examined by a pathologist, who was unaware of the parameters to be investigated. A total of 68 patients with periampullary cancers (29 ampulla of Vater cancers (AVCs) and 39 pancreatic ductal cancers (PDCs), including various stages and histological subtypes, were enrolled. The relevant demographic and clinicopathological information was obtained from medical records.
RESULTS: Cell-cycle proteins, including p16, Rb, cyclin D1, p53, and E2F1, were analyzed by immunohistochemical staining. Here, significant differences were noted between AVCs and PDCs with regard to the expression of cyclin D1. This corresponded to a poor prognosis in PDCs (P < 0.05); AVCs, on the other hand, showed a relatively high survival rate. There is no obvious statistical difference between the 2 groups with regard to the expression of p16, Rb, p53, and E2F1. The study also revealed that cyclin D1 plays different roles in the carcinogenesis of AVCs and PDCs.
CONCLUSIONS: The expression of cyclin D1 is more often correlated with prognosis in AVCs than in PDCs, and may serve as a biomarker for the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17420962     DOI: 10.1007/s00268-006-0032-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  26 in total

1.  Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.

Authors:  Sehwan Han; Kyeongmee Park; Byung-Noe Bae; Ki Hwan Kim; Hong-Joo Kim; Young-Duck Kim; Hong-Yong Kim
Journal:  Oncol Rep       Date:  2003 Jan-Feb       Impact factor: 3.906

2.  Image cytometry of cyclin D1: a prognostic marker for head and neck squamous cell carcinomas.

Authors:  S C Liu; S Y Zhang; J S Babb; J A Ridge; A J Klein-Szanto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-05       Impact factor: 4.254

3.  Reduced membranous and ectopic cytoplasmic expression of beta -catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer.

Authors:  Q Qiao; M Ramadani; S Gansauge; F Gansauge; G Leder; H G Beger
Journal:  Int J Cancer       Date:  2001-05-20       Impact factor: 7.396

4.  Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Authors:  R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

5.  K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.

Authors:  A Kawesha; P Ghaneh; A Andrén-Sandberg; D Ograed; R Skar; S Dawiskiba; J D Evans; F Campbell; N Lemoine; J P Neoptolemos
Journal:  Int J Cancer       Date:  2000-11-20       Impact factor: 7.396

6.  K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China.

Authors:  Asif Rashid; Takashi Ueki; Yu-Tang Gao; Patrick Scott Houlihan; Charita Wallace; Bing-Sheng Wang; Ming-Chang Shen; Jie Deng; Ann W Hsing
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

Review 7.  Cyclin-dependent kinase pathways as targets for cancer treatment.

Authors:  Geoffrey I Shapiro
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

8.  Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas.

Authors:  Sang Geol Kim; Annie On-On Chan; Tsung-Teh Wu; Jean-Pierre J Issa; Stanley R Hamilton; Asif Rashid
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

9.  Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer.

Authors:  O Belvedere; F Puglisi; C Di Loreto; P Cataldi; A Guglielmi; C Aschele; A Sobrero
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

10.  Carcinoma of the ampulla of Vater: results of surgical treatment of a single center.

Authors:  Muhammed Ashraf Memon; M Hanif Shiwani; Suhail Anwer
Journal:  Hepatogastroenterology       Date:  2004 Sep-Oct
View more
  1 in total

1.  The Association between Survival and the Pathologic Features of Periampullary Tumors Varies over Time.

Authors:  Jennifer K Plichta; Anjali S Godambe; Zachary Fridirici; Sherri Yong; James M Sinacore; Gerard J Abood; Gerard V Aranha
Journal:  HPB Surg       Date:  2014-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.